|
The US Food and Drug Administration (FDA) recently approved the first drug to receive a Rare Pediatric Disease Priority Review Voucher, a new FDA program that aims to encourage development of new drugs and biologics for the prevention and treatment of rare pediatric diseases by helping speed such agents to market. Read more |
